SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Lesser RS, Lee Walters J, Pebenito R, Klee S, Khan R. J. Clin. Rheumatol. 1997; 3(5): 294-298.

Copyright

(Copyright © 1997, Lippincott Williams and Wilkins)

DOI

10.1097/00124743-199710000-00011

PMID

unavailable

Abstract

Neuropsychiatric lupus erythematosus (NPLE) is a major cause of morbidity and mortality. We report a case involving an adolescent female who developed acute NPLE, manifesting as acute delusional depression with suicidal ideation. Despite high-dose corticosteroid therapy, these symptoms persisted. Within 7 to 10 days of initiation of paroxetine, a selective serotonin reuptake inhibitor (SSRI) and fluphenazine, an antipsychotic agent, the patient's neurovegetative symptoms of depression improved and suicidality remitted. Psychosis resolved with longer treatment. Undoubtedly these drugs were treating a psychiatric complication of the underlying disease. Our case supports the notion that some severe neuropsychiatric symptoms can be reversed without reliance upon immunosuppressants. It is premature to advocate unconditional acceptance of this approach, yet the findings in our case suggest that early adjunctive treatment with paroxetine and fluphenazine for steroid-resistant NPLE might spare a subset of patients the toxic effects and complications of immunosuppressants. This is the first report to describe a novel adjunctive treatment with the SSRI antidepressant, paroxetine. Our findings merit further investigation with larger numbers of patients.


Language: en

Keywords

Cerebritis; Fluphenazine; Neuropsychiatric lupus Erythematosus; Paroxetine; Pediatrics; Systemic lupus erythematosus

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print